- CYBN subsidiary Adelia Therapeutics has reached earn-out milestones.
- Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules.
- Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic compounds.
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that earn-out milestones have been reached by its wholly controlled subsidiary Adelia Therapeutics Inc. These milestones, which were for the period commencing Jan. 1, 2021, add value to Cybin’s pipeline of novel psychedelic compounds (https://ibn.fm/Y1YPb).
“These positive catalysts continue to provide the necessary data required to demonstrate that Cybin’s proprietary deuterated psychedelic molecules potentially carry the same pharmacodynamic properties, safety profiles, potency and receptor targeting as their parent molecules,” said Cybin CEO Doug Drysdale. “While the profiles are similar to parent molecules, early research has shown that these proprietary molecules also carry certain characteristics that may lead them to potentially become commercially viable because of their improved stability, bioavailability, controlled psychedelic duration and overall enhanced chemical make-up.”
Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules, the company reported. Those results determined that proprietary deuteration modifications in multiple-lead new chemical entity candidates did not alter pharmacodynamic properties and did not alter safety as assessed in in-vitro toxicity tests as compared to non-deuterated analogs. These promising results add value to the pipeline of proprietary novel psychedelic compounds that Cybin is developing.
The results, the company noted, demonstrate that “these molecules perform similarly to the naturally occurring molecules in certain important metrics. The development of these compounds differentiates Cybin from companies focused on naturally occurring psychedelic compounds.”
Cybin closed on its acquisition of Adelia in December 2020 in a move that Drysdale stated as “potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder.
“Adelia’s focuses on novel delivery methods and innovative therapies may contribute to our goal of therapies with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods and reduced side effects,” Drysdale continued. “Adelia’s expertise across multiple molecules and multiple indications could potentially give Cybin the ability to address gaps across a larger domain” (https://ibn.fm/XaFk4).
Cybin, a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
